In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors. 

While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach. 

Anocca is building a fully integrated platform that combines: Target mapping of HLA-peptide complexes Rapid generation of optimized T-cell receptors from healthy donors Non-viral gene editing for faster, lower-cost manufacturing End-to-end control from discovery through clinical development.

The conversation also highlights Anocca’s first clinical program targeting mutant KRAS in pancreatic ductal adenocarcinoma, using an umbrella trial design, early intervention strategies, and biomarkers such as circulating tumor DNA (ctDNA). Reagan shares insights on regulatory pathways for individualized therapies, the commercial challenges of patient segmentation, and how software, data, and machine learning are becoming essential to scaling cell therapy platforms. 

This episode is a must-listen for anyone interested in cell therapy innovation, cancer immunotherapy, and the future of precision medicine. 

Episode Timestamps 

00:00 – Introduction to TCR-T and solid tumor challenges 

00:48 – Meet Reagan Jarvis and Anocca 

02:05 – From New Zealand to Sweden: founder journey 

03:08 – Frustration that sparked the platform 

04:33 – Why CAR-T struggles in solid tumors 

07:24 – The advantage of vertical integration in biotech 

09:23 – First non-viral clinical trial challenges 

10:56 – Umbrella trials in pancreatic cancer (KRAS focus) 

14:13 – Biomarkers and building a target library 

17:08 – Software, data, and machine learning in TCR discovery 

18:08 – Regulatory pathways for individualized therapies 

19:19 – Commercial landscape and target bottlenecks 

22:29 – Expanding beyond oncology and partnerships 

23:51 – Building a biotech company in Sweden 

27:12 – Misconceptions about T-cell biology 

30:04 – Milestones and 5-year vision 

32:32 – Advice for scientific founders 

34:17 – Closing thoughts 

Don't forget to Like, Share, Subscribe, Rate, and Review!   

Keep up with Reagan Jarvis; 

LinkedIn: https://www.linkedin.com/in/reagan-jarvis-063984142/ 

Website: https://www.anocca.com/  

Follow IDEA Pharma 

Website: https://www.ideapharma.com/ 

LinkedIn: https://www.linkedin.com/company/idea-pharma/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations. 

After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and platform-driven innovation. 

The conversation dives into Vir Bio’s next chapter, including its masked T-cell engager (TCE) pipeline and the PRO-XTEN® masking platform, which is designed to overcome the safety challenges of TCEs in the treatment of solid tumors by shielding therapies until they reach the tumor microenvironment. 

They also discuss Vir Bio’s advancing hepatitis delta program, currently in registrational Phase 3 trials, and the company’s growing pipeline leveraging the synergy of its AI-driven discovery, protein engineering capabilities, and universal PRO-XTEN® masking technology. 

Marianne shares what it takes to lead through a biotech downturn—from restructuring and capital discipline to rebuilding culture, integrating new teams, and positioning for long-term growth. 

This episode is a deep dive into biotech turnaround strategy, next-generation cancer therapies, and leadership in times of uncertainty. Episode 

Timestamps 

00:00 – Introduction and Vir’s transformation story 

00:40 – Marianne De Backer’s 30+ year pharma journey 

02:42 – Vir’s origins and post-COVID strategic pivot 

04:42 – Taking over as CEO during a crisis 

06:33 – Lessons from the biotech downturn (“biotech winter”) 

08:56 – Astellas partnership and T-cell engager strategy 

09:52 – ProXtend platform: masked T-cell engagers explained 

13:24 – Clinical data, safety, and tumor targeting 

15:32 – Integrating new teams and scientific expertise 

17:38 – Expanding the pipeline (HER2, EGFR, oncology) 

19:50 – Hepatitis delta program and commercialization plans 

22:11 – Funding strategy and biotech market outlook 

25:37 – FDA interactions and regulatory perspective 

28:13 – AI in drug discovery and clinical trials (Daisy platform) 

31:34 – Culture: grit, ingenuity, collaboration, authenticity 

34:21 – Personal reflections and leadership mindset 

35:46 – Closing thoughts 

Don't forget to Like, Share, Subscribe, Rate, and Review!   

Keep up with Marianne De Backer; 

LinkedIn: https://www.linkedin.com/in/marianne-d-de-backer-msc-phd-mba-73403411/ 

Website: https://www.vir.bio/   

Follow IDEA Pharma On; 

Website: https://www.ideapharma.com/ 

LinkedIn: https://www.linkedin.com/company/idea-pharma  

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation. 

Episode Timestamps; 

00:00 Welcome to Idea Collider 

00:18 Kymera 2026 Catalysts 

02:33 De Risking with Degraders 

02:54 Targeted Protein Degradation 101 

06:20 KT-621 STAT6 Degrader

08:16 Rethinking Type 2 Disease Treatment

12:21 Nello’s Path to CEO 

16:32 Building a Standalone Biotech 

23:19 Partnering with Big Pharma 

26:51 Culture and Office Energy 

32:03 Capital Plan and Potential Launches

36:24 Belief and Execution Mindset 

39:00 Life Outside the Lab 

40:07 Where to Follow Kymera 

40:35 Closing Thanks 

Don't forget to Like, Share, Subscribe, Rate, and Review!   

Keep up with Nello Mainolfi & Kymera

LinkedIn: https://www.linkedin.com/in/nello-mainolfi-2b55421a/ or https://www.linkedin.com/company/kymeratherapeutics/

Website: https://www.kymeratx.com/   

Follow IDEA Pharma On; 

Website: https://www.ideapharma.com/ 

LinkedIn: https://www.linkedin.com/company/idea-pharma/   

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how organizations can move beyond data collection to drive smarter, more confident decision-making. 

Featuring insights from Erik Nordhoy, CEO of SAI MedPartners, alongside his team, John Barry, Matt Boucher, Jennifer Preston, and Lucia Fernandez Barreiros, this conversation examines how cross-functional teams can interpret insights, manage uncertainty, and improve portfolio outcomes in complex drug development environments. The discussion covers artificial intelligence, asymmetric learning, forecasting challenges, strategic alignment, and the leadership mindset required to navigate innovation in biopharma. 

SAI MedPartners is a global consultancy that provides strategic insights, competitive intelligence, market research, and commercialization strategy to pharmaceutical, biotechnology, and medical device companies across the product lifecycle. This episode is a must-listen for leaders working across drug development, commercialization strategy, and pharmaceutical innovation. 

Keep up with the guests; 

Erik Nordhoy - President at SAI MedPartners LLC https://www.linkedin.com/in/erik-nordhoy-6996241/ 

John Barry  - Executive Vice President at SAI MedPartners LLC https://www.linkedin.com/in/johnnbarry/ 

Matt Boucher, PhD - Director, Oncology BU, SAI MedPartners LLC https://www.linkedin.com/in/matthewbchr/ 

Jennifer Preston - VP, Artificial Intelligence Leader, SAI MedPartners LLC https://www.linkedin.com/in/jennifer-j-preston/ 

Lucia Fernandez Barreiros - Consulting Analyst, SAI MedPartners LLC https://www.linkedin.com/in/lucia-fernandez-barreiros-ba5260224/   

Follow Mike Rea On; 

Website: https://ideacollider.simplecast.com/ 

X: https://x.com/ideapharma 

LinkedIn: https://www.linkedin.com/in/bigidea/   

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases.

Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations — a single class of genetic errors that account for roughly 10% of genetic diseases, affecting millions worldwide. Rather than the traditional “one drug, one disease” model, Alltrna is pursuing a mutation-targeted strategy that could treat multiple diseases with a single therapeutic platform.

Episode Timestamps;

00:00 Welcome to Idea Collider: Asymmetric Learning in Pharma

00:19 Meet Michelle Werner: Leading Alltrna’s tRNA Platform

02:09 From Cancer Clinic to Pharma: A Patient-First Career Path

06:18 Big Pharma vs Biotech CEO: Finding Your Authentic Leadership Style

09:37 Vulnerability & Psychological Safety: Building High-Trust Teams

11:46 A Personal Turning Point: Her Son’s Duchenne Diagnosis

17:11 Rare Disease Renegades: A Nonprofit to Accelerate Innovation

18:19 Why Flagship Pioneering: The Ecosystem Behind Alltrna

22:31 tRNA 101: Targeting Stop-Codon Disease Across Thousands of Conditions

28:46 Rethinking Trials, Indications & FDA Pathways for Mutation-First Medicines

33:49 From Preclinical to First-in-Human: Alltrna’s 2026 Milestones

36:49 What Keeps a CEO Up at Night + Final Takeaway: Is This Rare Disease’s Inflection Point?

Michelle also reflects on how her personal experience as a parent of a child with a rare condition fuels her commitment to accelerating therapies for patients who currently have few or no options.

This episode highlights a pivotal question for the industry:

Are rare diseases at the same inflection point oncology experienced two decades ago?

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Michelle Werner;

LinkedIn: https://www.linkedin.com/in/michelle-c-werner/

Website: https://www.alltrna.com/

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovation at IDEA, reminisces about the early days leading to the successful positioning and market shaping of luspatercept across different hematological indications. The episode features insightful contributions from Robin, Jane, and Tracy, key players from Acceleron and Celgene, who share their experiences and the collaborative efforts that enabled them to redefine the market. The discussion covers the strategic approach to overcoming competitive benchmarking, the importance of a unified messaging strategy, and the critical role of internal and external collaboration. They also reflect on the impact of their efforts on the lives of many patients and offer advice for future teams working on complex drug development projects. The episode concludes with a recognition of the rare and valuable collaborative human elements that drove the success of the Reblozyl project.

Episode Timestamps;

00:00 Introduction and Welcome

00:27 Rick's Background and Project Overview

02:31 Client Team Introductions

05:32 Collaboration and Challenges

13:29 Defining the Mechanism and Market Positioning

23:52 Communication and Alignment

27:48 Navigating Internal and External Communication

33:15 Launch, Reflections, and Lessons Learned

41:14 Final Thoughts and Acknowledgements

Keep up with the guests;

• Robyn Blackburn  - Director Global Commercial Strategy CAR-T at Kite Pharma
  • https://www.linkedin.com/in/robyn-blackburn-805b8b13/
• Jayne Butler - Director of Strategic Initiatives at Fingerpaint Branding
  • https://www.linkedin.com/in/jaynebutler/
• Tracey Sacco - Former SVP Global Strategic Marketing at Acceleron
  • https://www.linkedin.com/in/tracey-sacco-53 2a034/
• Rick Ritacco - Head of Growth and Innovation
  • https://www.linkedin.com/in/rritacco/

Follow Mike Rea On;

Website: https://ideacollider.simplecast.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas in modern medicine: using one-time gene editing to permanently lower cholesterol and prevent heart disease.

Dr. Kathiresan shares his journey from immigrant upbringing to Harvard cardiologist, genetic researcher, biotech founder, and now leader inside a global pharmaceutical company. The conversation explores how human genetics, CRISPR base editing, lipid nanoparticle delivery, and asymmetric learning converged to create a potential lifelong solution to cardiovascular disease.

They also dive deep into the ethics of gene editing, global access and pricing, early intervention versus chronic care, FDA regulatory challenges, and what the Verve–Lilly acquisition means for the future of cardiometabolic medicine.

This episode is a must-listen for anyone interested in biotech innovation, gene therapy, cardiovascular disease, and the future of preventive medicine.

00:00 Introduction and Guest Welcome

01:16 Sekar Kathiresan's Early Life and Education

03:19 Founding Verve and Transition to Entrepreneurship

05:35 The Science Behind Verve's Mission

10:27 Challenges and Breakthroughs in Gene Editing

20:05 Regulatory Hurdles and First Human Trials

25:11 Ethical Considerations in Gene Editing

27:06 Introduction to Drug Delivery and Ethical Considerations

27:51 Historical Context and Pioneers in Medical Procedures

28:35 Commercial and Ethical Challenges in Medicine

29:32 Innovations in Cardiovascular Treatments

32:49 The Role of Gene Editing in Long-term Health

37:55 Strategic Partnerships and Industry Insights

45:08 Reflections on the US Medical Ecosystem

48:54 Conclusion and Future Outlook

Keep up with Sekar Kathiresan;

LinkedIn: https://www.linkedin.com/in/sekar-sek-kathiresan-3501846/

Website: https://www.lilly.com/

Follow Mike Rea On;

Website: https://ideacollider.simplecast.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows.

The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation!

00:00 Welcome to Idea Collider

00:04 Introducing Alex Telford

01:59 Alex's Journey from UCL to Convoke Bio

05:29 The Mission and Work of Convoke Bio

07:57 Challenges in Pharma Decision Making

14:05 The Role of AI in Pharma

18:26 Knowledge Management and AI

27:58 Staying Updated in the Fast-Moving AI Field

30:25 AI's Impact on Industry Economics

31:38 AI in Clinical Trials and Drug Development

35:56 China's Role in Drug Discovery

39:24 Neuroscience and AI: Blurring the Lines

46:05 Future Predictions in Pharma

51:20 Addressing Cognitive Bias in Pharma

53:13 Concluding Thoughts and Future Directions

Keep up with Alex Telford;

LinkedIn: https://www.linkedin.com/in/alexander-telford/

Website: atelfo.github.io

X: https://twitter.com/atelfo

Substack: atelfo.substack.com

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation.

00:00 Introduction and Guest Welcome

00:25 Christian Rommel's Journey in Oncology

03:02 The Importance of Collaboration in Innovation

05:16 Balancing Risk and Reward in Drug Development

18:07 The Role of AI and Data in Modern R&D

22:33 Partnerships and External Learning

26:16 Balancing Legacy and Innovation in Biotech

27:18 Global Expansion and Leadership Diversity

27:27 Courage in Biotech Management

27:54 Inspiration from Roche Genentech

30:26 Commitment to Product Supply and Market Readiness

32:23 Challenges of Global Launches

35:53 Emerging Trends in Pharma: AI and Genetic Medicines

42:20 Decision-Making in Pharma

47:30 Reflections on Academic and Professional Journey

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Christian Rommel;

LinkedIn: https://www.linkedin.com/in/christian-rommel/

Website: https://www.bayer.com/en/innovation/science-research-and-innovation

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies.

00:00 Introduction and Guest Background

00:56 Founding Thebans and Career Highlights

01:43 Leadership at Merck and J&J

02:18 Innovative Approaches at Parabilis Medicines

04:09 Defining and Tackling Undruggable Targets

09:27 Multivalent Drug Design and Bispecifics

13:53 AI and Data Science in Drug Development

19:28 Building and Leading World-Class Teams

25:41 The Importance of Holding Conviction as an Entrepreneur

26:25 Learning from Setbacks in the Biotech Industry

30:10 Challenges and Innovations in Drug Development

32:28 Navigating the Ups and Downs of the Biotech Industry

36:02 The Mission and Future of Parabilis

40:35 Personal Reflections and Advice for Entrepreneurs

46:46 Book Recommendations and Closing Thoughts

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Mathai Mammen;

LinkedIn: https://www.linkedin.com/in/mathai-mammen/

Website: https://parabilismed.com/

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shares pivotal moments in his career, the challenges of transitioning from academia to big pharma, and the innovative principles he applied. He dives deep into Candel’s promising work in viral immunotherapies for cancers and the unique leadership and management philosophies that have guided his journey. Additionally, Paul Peter touches on his passion for leveraging collective intelligence and his unconventional hobbies that keep him grounded and creative.

00:00 Introduction and Guest Welcome

00:59 Early Career and Passion for Medicine

02:09 Transition to Industry and GSK Experience

04:50 Building Successful Organizations

07:42 Innovative Models in Pharma

19:03 Joining Candel Therapeutics and Vision for the Future

25:15 Transforming Cancer Treatment

27:24 Challenges in Biotech Market

28:45 Strategic Decisions and Prioritization

31:39 Collaborations and External Partnerships

33:07 Innovative Approaches and Future Prospects

44:23 Leadership and Personal Insights

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Paul Peter Tak;

LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/